Amgen Stock Rises on Strong Guidance and Repatha Sales

Amgen stock has seen gains due to higher guidance and strong performance from its cardiovascular drug Repatha. On September 3, 2026, Amgen traded at USD 439.51 with a market capitalization of USD 239.41 billion. The company's quarterly earnings of USD 6.29 per share on revenue of USD 10.05 billion beat consensus expectations.

The revenue increase of 9.5 percent year over year is also notable, as well as the company's raised FY 2026 guidance to USD 22.30 to USD 23.50 in non-GAAP EPS. Repatha's sales growth is particularly significant, with second-quarter 2026 sales reaching USD 953 million, a 37 percent increase from the previous year.

While the UK suspension of Tavneos for new patients may be a concern, Repatha's strong performance has helped Amgen's stock stay firm. The product remains the best example of how Amgen can turn clinical readouts into commercial scale.